Environmental Surveillance for Risk Assessment in the Context of a Phase 2 Clinical Trial of Type 2 Novel Oral Polio Vaccine in Panama

Environmental surveillance was recommended for risk mitigation in a novel oral polio vaccine-2 (nOPV2) clinical trial (M5-ABMG) to monitor excretion, potential circulation, and loss of attenuation of the two nOPV2 candidates. The nOPV2 candidates were developed to address the risk of poliovirus (PV)...

Descripción completa

Detalles Bibliográficos
Autores principales: Rojas-Bonilla, Magda, Coulliette-Salmond, Angela, Belgasmi, Hanen, Wong, Kimberly, Sayyad, Leanna, Vega, Everardo, Grimoldi, Fabian, Oberste, M. Steven, Rüttimann, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310065/
https://www.ncbi.nlm.nih.gov/pubmed/34372561
http://dx.doi.org/10.3390/v13071355

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310065/
https://www.ncbi.nlm.nih.gov/pubmed/34372561
http://dx.doi.org/10.3390/v13071355

Ejemplares similares